drugset

drugset / Trial / NCT00137774

Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors

NCT00137774 ↗

Phase 2 Completed 34 enrolled Dana-Farber Cancer Institute Beth Israel Deaconess Medical Center · collab Brigham and Women's Hospital · collab Genentech, Inc. · collab Massachusetts General Hospital · collab Schering-Plough · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine what effects (good and bad) bevacizumab and temozolomide have on patients with neuroendocrine tumors.

Timeline

Start: 2004-11
Primary completion: 2005-07
Completion: 2012-12

Publications

Results Chan JA, Stuart K, Earle CC, Clark JW, Bhargava P, Miksad R, Blaszkowsky L, Enzinger PC, Meyerhardt JA, Zheng H, Fuchs CS, Kulke MH. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol. 2012 Aug 20;30(24):2963-8. doi: 10.1200/JCO.2011.40.3147. Epub 2012 Jul 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	5 mg/kg	Intravenous
Subject	Temozolomide	Small molecule	150 mg/m2	Oral

Indications